Introducing a New Antifungal Surveillance Program: Analysis of Resistance to Antifungals (ARIA) and Expanded Mycology Services at IHMA
7.10.2021 17:00:00 EEST | Business Wire | Press release
International Health Management Associates (IHMA) has initiated a new antifungal resistance surveillance program, Analysis of Resistance to Antifungals (ARIA) to further the development of new antifungal agents and monitor the development of antifungal resistance.
ARIA collects and determines the antifungal susceptibility of clinically-relevant Candida spp., which includes the emerging C. auris, filamentous fungi, and also rarer molds from hospitals world-wide, including China and India. IHMA offers an option for biopharmaceutical companies to add new antifungal agents to the program.
The first presentation of ARIA data - Analysis of Resistance In Antifungals (ARIA) - Global Surveillance of Candida spp. Isolates, Including C. auris, in 2019 - will be made at the upcoming 10th Trends in Medical Mycology (TIMM-10), 8-11 October 2021, Aberdeen, Scotland.
The ARIA program greatly enhances IHMA's pre-clinical and clinical mycology capabilities at the European facility (Monthey, Switzerland) to profile new products, molecularly characterize antifungal resistance mechanisms, and serve as a central laboratory for clinical trials.
“IHMA is continuously looking for new ways to help clients progress with their new anti-infective agent programs. Our ability to adapt and add new capabilities shows our flexibility, dedication, and interest in assisting clients in the ongoing fight against antimicrobial resistance. The addition of mycology services augments our goal to support the biopharmaceutical industry by providing a suite of premier microbiology services to clients wishing to conduct antifungal studies on a global scale,” said Jack L. Johnson, President/CEO of IHMA.
About IHMA:
As the leading global microbiology service provider to the biopharmaceutical industry, IHMA utilizes its extensive laboratory and industry expertise to support efficient and effective anti-infective product development. IHMA is a premier provider of reference laboratory services to support anti-infective product discovery and development as well as the development of diagnostic devices that detect bacterial resistance to antimicrobial agents and new technologies as they emerge.
For more information, please visit IHMA’s website (www.ihma.com).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005044/en/
Contact information
Darcie Carpenter PhD CIC
Director Global Business Development
+1.530.577.5296
dcarpenter@ihma.com
Ian Morrissey MBA PhD FRSM
Chief Scientific & Development Officer
+44.01279.724929
imorrissey@ihma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 16:36:00 EEST | Press release
MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also incl
Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 16:00:00 EEST | Press release
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction Transactions Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million. Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million. “Our year-to-date share repurchases
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom